Q3 FY2026 · ended Sep 30, 2026 · Revenue $193.40M, +15.7% YoY · Filed Oct 29, 2026
NovoCure Limited (NVCR) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $193.4 million and a net loss of $10.4 million. Free cash flow was $15.7 million. As of Sep 30, 2026 it held $96.7 million in cash and investments and $60.2 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- NVCR (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- St. Helier
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1645113
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $193.4M | $183.6M | $174.1M | $174.3M | $167.2M |
| Operating income | -$6.2M | -$10.6M | -$67.4M | -$40.4M | -$36.0M |
| Net income | -$10.4M | -$15.7M | -$71.1M | -$24.5M | -$37.3M |
| Diluted EPS | -$0.09 | -$0.13 | -$0.62 | -$0.22 | -$0.33 |
| Operating cash flow | $22.7M | $8.1M | -$13.5M | -$18.0M | $20.6M |
| Free cash flow | $15.7M | $1.2M | -$18.7M | -$22.9M | $14.9M |
| Total assets | $828.7M | $795.2M | $787.9M | $804.3M | $1.4B |
| Total liabilities | $478.1M | $457.1M | $457.2M | $463.9M | $1.0B |
| Stockholders' equity | $350.6M | $338.1M | $330.7M | $340.5M | $341.3M |
| Cash and investments | $96.7M | $93.7M | $87.5M | $93.5M | $342.1M |
| Total debt | $60.2M | $37.5M | $39.5M | $248.4M | $42.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 9, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Other events
|
Sep 1, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 23, 2026 | Jul 23, 2026 |
All 1000 NovoCure Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.